Shanghai Labway Clinical Laboratory Co., Ltd. (301060.SZ)
CNY 8.9
(0.34%)
CNY 8.9
(0.34%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 1.67 Billion | 4.19 Billion | 1.77 Billion | 1.23 Billion | 1.15 Billion | 1.05 Billion |
| Cost of Revenue | 1.34 Billion | 2.4 Billion | 1.09 Billion | 838.35 Million | 805.03 Million | 727.84 Million |
| Gross Profit | 329.31 Million | 1.79 Billion | 679.89 Million | 399.83 Million | 348.46 Million | 324.88 Million |
| Operating Expenses | 479.96 Million | 644.59 Million | 349.35 Million | 212.7 Million | 211.23 Million | 209.26 Million |
| Selling, General and Administrative Expenses | 157.86 Million | 274.63 Million | 188.68 Million | 20.43 Million | -220.32 Million | -258.86 Million |
| Research and Development Expenses | 48.86 Million | 109.4 Million | 39.44 Million | 21.8 Million | 18.8 Million | 16.88 Million |
| Other Expenses | - | 260.55 Million | 121.22 Million | 170.47 Million | 412.75 Million | 15.72 Million |
| Cost and Expenses | 1.81 Billion | 3.05 Billion | 1.44 Billion | 1.05 Billion | 1.01 Billion | 937.11 Million |
| Operating Income | -135.82 Million | 949.27 Million | 318.94 Million | 178.46 Million | 130.55 Million | 106.67 Million |
| Interest Expense | 8.17 Million | 8.45 Million | 3.26 Million | 401.39 Thousand | 5.21 Million | 20.07 Million |
| Income Tax Expense | 8.46 Million | 165.38 Million | 56.41 Million | 27.82 Million | 31.69 Million | 31.71 Million |
| Earnings before Tax | -153.24 Million | 904.44 Million | 318.03 Million | 162.3 Million | 126.31 Million | 105.65 Million |
| Net Income | -141.59 Million | 617.32 Million | 203.84 Million | 110.37 Million | 92.24 Million | 73.38 Million |
| Earnings Per Share Basic | -0.35 | 1.54 | 0.51 | 0.28 | 0.23 | 0.21 |
| Earnings Per Share Diluted | -0.35 | 1.54 | 0.51 | 0.28 | 0.23 | 0.21 |
| Weighted Average Shares Outstanding | 400.54 Million | 400.51 Million | 400.51 Million | 400.51 Million | 400.51 Million | 352.47 Million |
| Weighted Average Shares Outstanding (Diluted) | 400.54 Million | 400.51 Million | 400.51 Million | 400.51 Million | 400.51 Million | 352.47 Million |
| Gross Margin | 0.20 | 0.43 | 0.38 | 0.32 | 0.30 | 0.31 |
| EBIT Margin | -0.04 | 0.28 | 0.22 | 0.20 | 0.17 | 0.21 |
| Profit Margin | -0.08 | 0.15 | 0.11 | 0.09 | 0.08 | 0.07 |
| EBITDA | -59 Million | 1.01 Billion | 392.49 Million | 215.63 Million | 175.2 Million | 148.5 Million |
| Earnings Before Tax Margin | -0.08 | 0.23 | 0.18 | 0.14 | 0.11 | 0.10 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 429.21 Million | 450.4 Million | 436.44 Million | 1.67 Billion | 404.49 Million | 431.96 Million |
| Cost of Revenue | 356.78 Million | 355.3 Million | 340.83 Million | 1.32 Billion | 367.23 Million | 336.35 Million |
| Gross Profit | 72.43 Million | 95.1 Million | 95.6 Million | 348.28 Million | 37.25 Million | 95.61 Million |
| Operating Expenses | 151.92 Million | 88.4 Million | 68.31 Million | 322.39 Million | 103.13 Million | 82.7 Million |
| Selling, General and Administrative Expenses | 73.01 Million | 67.93 Million | 59.1 Million | - | -47.3 Million | 136.93 Million |
| Research and Development Expenses | 15.44 Million | 17.39 Million | 9.98 Million | - | 16.16 Million | 13.06 Million |
| Other Expenses | -63.46 Million | -3.07 Million | -402.24 Thousand | -17.41 Million | -12.26 Million | -158.45 Thousand |
| Cost and Expenses | 508.7 Million | 443.71 Million | 409.15 Million | 1.64 Billion | 470.37 Million | 419.05 Million |
| Operating Income | -79.48 Million | 6.69 Million | 2.72 Million | -135.82 Million | -141.49 Million | 11.8 Million |
| Interest Expense | 2.15 Million | 3.04 Million | 2.84 Million | 8.17 Million | 1.93 Million | 2.32 Million |
| Income Tax Expense | -12.59 Million | -1.47 Million | 2.58 Million | 8.46 Million | -1.41 Million | 3.21 Million |
| Earnings before Tax | -75.6 Million | 9.36 Million | 2.31 Million | -153.24 Million | -153.75 Million | 11.64 Million |
| Net Income | -56.18 Million | 14.52 Million | 1.07 Million | -141.59 Million | -140.71 Million | 942.55 Thousand |
| Earnings Per Share Basic | -0.14 | 0.04 | 0.00 | - | -0.35 | 0.00 |
| Earnings Per Share Diluted | -0.14 | 0.04 | 0.00 | - | -0.35 | 0.00 |
| Weighted Average Shares Outstanding | 398.87 Million | 398.87 Million | 396.93 Million | 400.54 Million | 402.07 Million | 400.51 Million |
| Weighted Average Shares Outstanding (Diluted) | 398.87 Million | 398.87 Million | 396.93 Million | 400.54 Million | 402.06 Million | 400.51 Million |
| Gross Margin | 0.17 | 0.21 | 0.22 | 0.21 | 0.09 | 0.22 |
| EBIT Margin | -0.17 | 0.07 | 0.07 | - | -0.19 | 0.03 |
| Profit Margin | -0.13 | 0.03 | 0.00 | -0.08 | -0.35 | 0.00 |
| EBITDA | -73.44 Million | 30.66 Million | 30.1 Million | - | -77.06 Million | 13.98 Million |
| Earnings Before Tax Margin | -0.19 | 0.01 | 0.01 | -0.08 | -0.35 | 0.03 |
603010
NYR
CWP
4456
HLEGLAS
SVAV